ARA-290 (Cibinetide) (16 mg Vial) Dosage Protocol
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin (EPO) that retains tissue-protective and anti-inflammatory effects without erythropoietic activity.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (2.0 mL = 8 mg/mL)
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 2 mg (2,000 mcg) | 25 units (0.25 mL) |
| Weeks 2–8 (or up to 16) | 4 mg (4,000 mcg) | 50 units (0.50 mL) |
Frequency: Inject once daily subcutaneously. Clinical studies used 4 mg/day as the target therapeutic dose, with no additional benefit observed at 8 mg. Starting at 2 mg for the first week allows assessment of individual tolerance before reaching the maintenance dose.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl or roll until fully dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration (2 mg week 1, then 4 mg daily).
| Item | Quantity |
|---|---|
| Peptide Vials (Ara-290, 16 mg each) | 8 weeks: approximately 14 vials required 12 weeks: approximately 21 vials required 16 weeks: approximately 28 vials required |
| Insulin Syringes (U-100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (14 vials): 28 mL — 3 bottles required (10 mL each) 12 weeks (21 vials): 42 mL — 5 bottles required (10 mL each) 16 weeks (28 vials): 56 mL — 6 bottles required (10 mL each) |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs — 2 boxes required (100 swabs each) 12 weeks: 168 swabs — 2 boxes required (100 swabs each) 16 weeks: 224 swabs — 3 boxes required (100 swabs each) |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
How This Works
ARA-290 is derived from helix B of EPO and binds the innate repair receptor (IRR — a tissue-protective receptor distinct from EPO's erythropoietic receptor). It produces anti-inflammatory and tissue-protective effects without raising hematocrit.
Potential Benefits & Side Effects
Potential Benefits
- Anti-inflammatory effects via IRR.
- Studied in diabetic neuropathy and sarcoidosis-related neuropathy.
- No erythropoietic effect — separate from EPO's blood effects.
Side Effect Profile
- Generally well-tolerated in trials.
- Mild injection-site reactions.
Lifestyle Factors
- Anti-inflammatory diet complements effects.
- Adequate B-vitamins support nerve health.
Injection Technique
- Subcutaneous, rotate sites.